Press release

Medios AG: Annual General Meeting re-elects Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board

Berlin, June 21, 2023 – The shareholders of Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, have approved the resolutions proposed by the Executive Board and the Supervisory Board at today's Annual General Meeting with large majorities, apart from one exception. The new Authorized Capital 2023 proposed jointly by the Executive Board and the Supervisory Board did not receive approval.

This year, the Annual General Meeting took place as an attendance event in Berlin, after it had been held in virtual form – without the physical presence of shareholders – in the three previous years due to the pandemic. In total, around 74% of the share capital voted. In his speech, the Executive Board explained, among other things, the progress and further developments of the adjusted growth strategy and expressed satisfaction with what has been achieved so far.

Matthias Gaertner, CEO of Medios AG: "In an environment that remains challenging, we are maintaining our profitable growth course. Thereby, our goals are based on three pillars: We want to strengthen our core business in Germany, roll out our highly successful business model tested in this country to other European countries, and enter the field of personalized medicine to further diversify and sustainably increase margin potential."

The shareholders discharged the members of the Executive Board and Supervisory Board for the 2022 financial year and endorsed the Management’s proposal to carry forward the unappropriated profit reported as of December 31, 2022. Another resolution adopted at the Annual General Meeting was the approval of the compensation report.

The Annual General Meeting re-elected the current members Dr. Yann Samson, Joachim Messner and Klaus J. Buß to the Supervisory Board. Their election will be valid until the end of the Annual General Meeting 2026, which will decide on the discharge for the 2025 financial year. With the re-election of the three Supervisory Board members, the shareholders sent a signal of continuity in this body.

Finally, the shareholders reappointed Baker Tilly GmbH Wirtschaftsprüfungsgesellschaft, Düsseldorf, Munich branch, as auditors of the annual financial statements and consolidated financial statements for the 2023 financial year and as auditors for any necessary review of interim financial reports until the next Annual General Meeting.

An overview of the detailed voting results of this year's Annual General Meeting can be found on the Medios AG website at .

Important dates for Medios AG in 2023 financial year:

August 14:  Half-Year Financial Report (Q2 & H1 2023)

September 20: Berenberg and Goldman Sachs 12th German Corporate

Conference - Munich

November 14: Quarterly Statement (Q3 and 9M 2023)

November 17: Warburg "Meet the Future" - Berlin

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T 800

Anna Höffken

Senior Consultant Investor & Public Relations

Kirchhoff Consult AG

Borselstraße 20 | 22765 Hamburg

T 34

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.